A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3

Trial Profile

A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Venglustat (Primary) ; Imiglucerase
  • Indications Gaucher's disease type I; Gaucher's disease type III
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms LEAP
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 02 Jan 2017 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
    • 02 Jan 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2022.
    • 06 Dec 2016 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top